This clinical trial is focused on studying a condition known as relapsing-remitting multiple sclerosis, a type of multiple sclerosis where patients experience periods of new or worsening symptoms followed by periods of recovery. The study is investigating a treatment called natalizumab, which is used to help manage this condition. Natalizumab is administered in two forms: as a concentrate for solution for infusion, known as Tysabri and Tyruko, and as a solution for injection in a pre-filled syringe, also under the name Tysabri.
The purpose of the study is to explore the safety and practicality of a personalized approach to dosing natalizumab at extended intervals, starting from every six weeks. This approach is being tested in a large group of people in the Netherlands who are living with relapsing-remitting multiple sclerosis. The study will monitor participants over a period of time to see how their condition responds to this dosing schedule.
Participants in the study will receive natalizumab through either an intravenous infusion, which means the medication is given directly into a vein, or through a subcutaneous injection, which is an injection under the skin. The study will track the activity of the disease using MRI scans to look for any new or growing lesions in the brain over a two-year period. This will help researchers understand the effects of the extended dosing schedule on the disease’s progression.
The Netherlands 
